Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 12/20 | 0.49 |
| ▸ | CDK9 | P50750 | 12/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004883 | 1.00 | CCNT1 (0.49) | CCNT1CDK9NAMPTEGFRIRAK4 | |
| SCHEMBL5009945 | 0.99 | CCNT1 (0.48) | CCNT1CDK9NAMPTEGFRIRAK4 | |
| SCHEMBL5004753 | 0.98 | CCNT1 (0.47) | CCNT1CDK9NAMPTEGFRIRAK4 | |
| SCHEMBL5005015 | 0.94 | CCNT1 (0.44) | CCNT1CDK9NAMPTEGFR | |
| SCHEMBL5004929 | 0.93 | CCNT1 (0.42) | CCNT1CDK9EGFRIRAK4 | |
| SCHEMBL5004741 | 0.93 | CCNT1 (0.41) | CCNT1CDK9NAMPTEGFR | |
| SCHEMBL5010289 | 0.93 | CCNT1 (0.41) | CCNT1CDK9NAMPTEGFR | |
| SCHEMBL5005884 | 0.92 | CCNT1 (0.42) | CCNT1CDK9IRAK4 | |
| SCHEMBL5004837 | 0.92 | CCNT1 (0.40) | CCNT1CDK9NAMPTEGFR | |
| SCHEMBL5010248 | 0.92 | CCNT1 (0.43) | CCNT1CDK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1797054-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006017443-A2 | ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | CCNT1 1580/4885CDK9 428/4885NAMPT 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.